LAVAL, QC, Sept. 12 /CNW Telbec/ - The Board of Directors of Neptune
Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) decided not to
re-price any options including the previously announced 850,000 options owned
by officers and directors.
About Neptune Technologies
Neptune researches and develops proprietary bioactive ingredients and
products for nutraceutical and pharmaceutical applications and is sponsoring
clinical research to demonstrate the therapeutic benefits in various medical
indications. The Company patents its intellectual property, protects its
industrial secrets and innovations and continuously expands its intellectual
property portfolio. Neptune has already obtained many regulatory approvals
allowing commercialization of its products in various geographic markets and
has filed for and is expecting additional approvals. Neptune continues to
strongly support its strategic development plan to form partnerships with
worldwide leaders in the nutraceutical industries. Neptune has signed
agreements with Nestlé and Yoplait, worldwide leading food manufacturers, and
paved its entrance into the global functional food market.
Neither NASDAQ nor TSX venture exchange accepts responsibility for the
adequacy or accuracy of this press release.
Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.
For further information:
For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
firstname.lastname@example.org; www.neptunebiotech.com; Source: Neptune
Technologies & Bioressources Inc.